Further evaluation of the CD4 and CD8 T cell contribution in the prevention of the second CT-26 challenge revealed that the mice cured with pTRG were depleted of CD4 and CD8 cells; these CD4- and CD8-depleted mice were not protected against the second CT-26 challenge, as evidenced by the tumor growth in their lungs (Fig. 5E). Here, CD8A is linked to neoplasm.